Welcome to the e-CCO Library Archive!

Filter:
P318. Kinetics of the anti-HBs titers after vaccination against hepatitis B virus (HBV) in patients with inflammatory bowel disease (IBD)
P318. Mapping of Crohn's disease in Northern France: Spatial and temporal variations of incidence between 1990 and 2006
P318. The prevalence of anaemia in inflammatory bowel disease in relation to disease activity, as stratified by faecal calprotectin
Authors:

M. Muscat1, N.A. Kennedy1, J. Chang1, F. Fascí Spurio1, J. Satsangi1, I.D. Arnott1, K. Kingstone2, C. Lees1, 1Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, 2Western General Hospital, Clinical Biochemistry, Edinburgh, United Kingdom

P318

Management of loss of response to infliximab. Results of a descriptive study of a cohort of inflammatory bowel disease patients.

Authors:

E. Ferrand1, D. Ternant2, L. Picon1, D. Moussata1, A. Aubourg*1

1CHRU Tours, Hepatogastroenterology, Tours, France, 2CHRU Tours, Pharmacology, Tours, France

P319.

The prevalence and clinical characteristics of refractory Crohn's disease in South China

Authors:

Y. He, P. Xu, Z. Zeng, B. Chen, R. Mao, K. Chao, M. Chen, The First Affiliated Hospital of SunYat-Sen University, Gastroenterology, Guangzhou, China

P319. Dose variations with adalimumab and infliximab in the treatment of Crohn's disease: A Canadian assessment
P319. Effectiveness of leukocyte adsorber LA25 in the treatment of inflammatory bowel disease (IBD) patients non-responder to conventional therapy: pilot study LEUKOSMART
Authors:

M. Di Girolamo1, A. Scarcelli1, A. Bertani1, A. Sartini1, A. Merighi1, E. Villa1, 1Policlinico Modena, Italy

P319. Inflammatory uncomplicated phenotype at the start of biological therapy predicts best surgery-free outcomes
P319

Adalimumab long-term effectiveness in adults with Crohn's Disease: Observational data from the PYRAMID registry

Authors:

E.V. Loftus Jr*1, G. D'Haens2, W. Reinisch3, 4, J. Satsangi5, R. Panaccione6, R. Thakkar7, S. Eichner8, K. Wallace9, A. Deshmukh10, S. Wang11, M. Skup11, J. Chao11, Y. Bao11

1Mayo Clinic, Division of Gastroenterology & Hepatology, Rochester, United States, 2Academic Medical Center, Gastroenterology, Amsterdam, Netherlands, 3Medical University of Vienna, Internal Medicine, Vienna, Austria, 4McMaster University, Internal Medicine, Hamilton, Canada, 5Western General Hospital, Edinburgh, United Kingdom, 6University of Calgary, Medicine, Calgary, Canada, 7AbbVie Inc., Global Pharmaceutical Research & Development , North Chicago, IL, United States, 8AbbVie Inc., Global Medical Affairs, North Chicago, IL, United States, 9AbbVie Inc., Immunology/Gastroenterology, North Chicago, IL, United States, 10AbbVie Inc., Statistics, North Chicago, IL, United States, 11AbbVie Inc., Global Health Economics and Outcomes Research, North Chicago, IL, United States

P319a

Deep clinical remission in patients with Ulcerative Colitis: Evaluating the effects of vedolizumab on various combinations of endoscopic and patient-reported outcomes

Authors:

W. Sandborn*1, J.-F. Colombel2, R. Panaccione3, K. Lasch4, S. Sankoh5, B. Abhyankar6

1University of California San Diego, Division of Gastroenterology, La Jolla, United States, 2Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States, 3University of Calgary, Department of Medicine, Calgary, Canada, 4Takeda Pharmaceuticals International, Inc., GI Medical Affairs, US Region, Deerfield, United States, 5Takeda Pharmaceuticals International Co., Global Statistics, Cambridge, United States, 6Takeda Global Research & Development Centre (Europe) Ltd., GI Clinical Science, London, United Kingdom

Table

P320.

The presence of fistulae at baseline does not increase the incidence of adverse events in patients with Crohn's disease in the infliximab ENCORE registry

Authors:

G. D'Haens1, W. Reinisch2, J.-F. Colombel3, J. Panes4, S. Ghosh5, C. Prantera6, S. Lindgren7, D.W. Hommes8, Z. Huang9, S. Huyck10, D.K. Chitkara11, 1Academic Medical Center, Inflammatory Bowel Disease Centre, Amsterdam, Netherlands, 2Medical University, Department of Internal Medicine III, Vienna, Austria, 3Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States, 4Hospital Clinic I Provincial, Department of Inflammatory Disease, Barcelona, Spain, 5University of Calgary, Department of Medicine, Calgary, Canada, 6AO San Camillo Forlianini, Gastroenterology Operative Unit, Rome, Italy, 7University Hospital MAS, Department of Gastroenterology, Malmö, Sweden, 8University of California Los Angeles, Center for Inflammatory Bowel Diseases, Los Angeles, United States, 9Merck Sharp & Dohme, Department of Epidemiology, Kenilworth, United States, 10Merck Sharp & Dohme, Department of Statistics, Merck Research Laboratories, Kenilworth, United States, 11Merck Sharp & Dohme, Department of Clinical Research, Kenilworth, United States

P320. Factors determining therapeutic strategy at diagnosis and evolution of disease severity in a cohort of Belgian pediatric Crohn's disease patients (BELCRO)
P320. Prevalence of inflammatory bowel disease is high in Finland
P320. What's the evidence-base for treating mental health co-morbidities in IBD?
Authors:

A. Mikocka-Walus1, J. Andrews2, 1University of South Australia, Nursing and Midwifery, Adelaide, Australia, 2Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia

P320

Clinical relevance of faecal calprotectin variability in Inflammatory Bowel Disease

Authors:

V. Kristensen*1, 2, G.H. Malmstrøm1, V. Skar1, B. Moum2, 3

1Lovisenberg Diakonale Hospital, Unger-Vetlesen`s Institute, Oslo, Norway, 2University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 3Oslo University Hospital, Department of Gastroenterology, Oslo, Norway

P321.

The one-year efficacy of infliximab does not depend on the timing of biological therapy in ulcerative colitis

Authors:

T. Molnar1, A. Bálint1, T. Nyári2, K. Farkas1, R. Bor1, Z. Szepes1, F. Nagy1, P. Miheller3, Á. Csontos3, G. Horváth4, P.L. Lakatos5, P.A. Golovics5, K. Palatka6, T. Wittmann1, 1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary, 3Semmelweis University, 2nd Department of Medicine, Budapest, Hungary, 4Semmelweis Health Center, Department of Gastroenterology, Miskolc, Hungary, 5Semmelweis University, First Department of Medicine, Budapest, Hungary, 6University of Debrecen, 2nd Department of Medicine, Debrecen, Hungary

P321. Paediatric IBD – How reliably does the Montreal classification perform?
P321. Recurrence of Crohn's disease after definitive stoma: A retrospective study in 83 patients
P321. Vitamin D level doesn't correlate with disease extent and severity in Hungarian patients with inflammatory bowel disease
Authors:

K. Lorinczy1, P.L. Lakatos2, Á. Salamon3, A. Nemes3, B. Fekete1, O. Terjék1, Á. Csontos1, T. Pere3, L. Herszényi1, Z. Tulassay1, P. Miheller1, 1Semmelweis University, 2nd Department of Internal Medicine, Budapest, Hungary, 2Semmelweis University, 1nd Department of Internal Medicine, Budapest, Hungary, 3János Balassa Tolna County Hospital, Department of Gastroenterology, Szekszárd, Hungary

P321

Postoperative complications after ileo-caecal resection for Crohn's Disease: a prospective multicentre study.

Authors:

M. Fumery*1, P. Seksik2, M. Chirica3, J.-M. Gornet4, G. Boschetti5, E. Cotte6, A. Buisson7, M. Nachury8, P. Zerbib9, X. Treton10, Y. Panis11, P. Marteau12, K. Pautrat13, C. Sabbagh14, J. filippi15, M. Allez4

1Amiens University Hospital, Hepatogastroenterology, Amiens, France, 2Hopital Saint Antoine , Gastroenterology , Paris, France, 3APHP, Hopital Saint Louis, Digestive surgery, Paris, France, 4APHP, Hopital Saint Louis, Department of Gastroenterology, Paris, France, 5CHU Lyon, Gastroenterology, Lyon, France, 6CHU Lyon, Digestive surgery, Lyon, France, 7CHU de Clermont-Ferrand, Department of Gastroenterology, Clermont-Ferrand, France, 8CHU Lille, Gastroenterology, Lille, France, 9CHU Lille, Digestive surgery, Lille, France, 10Beaujon Hospital, Department of Gastroenterology, Clichy la Garenne, France, 11Beaujon Hospital, Colorectal Surgery, Clichy, France, 12Hopital Lariboisiere, Gastroenterology, Paris, France, 13Hopital Lariboisiere, Digestive surgery, Paris, France, 14Amiens University Hospital, Digestive Surgery, Amiens, France, 15CHU de Nice, Department of Gastroenterology, Nice, France